**Multiple IPOs are scheduled to price in mid-October 2026, including Iambic Therapeutics (NASDAQ: IAM) targeting $150 million and City Therapeutics (CTY) aiming for roughly $175 million, with additional biotech and tech offerings in the pipeline through year-end.** The U.S. market has already seen elevated 2026 activity, with first-half proceeds exceeding $137 billion and Q3 volume supported by larger deals despite selective conditions and Treasury yield volatility near 19-year highs. Hong Kong listings have raised over HK$388 billion year-to-date, driven by A+H and specialist technology issuers. Key near-term catalysts include the October 15–16 U.S. debuts and potential November timing for names like Anthropic, while OpenAI has signaled a 2027 target. These developments, backed by real capital commitments in a constructive but discerning equity window, underpin strong trader consensus on near-term listings.